Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 2/20 | 0.30 |
| ▸ | GABRD | O14764 | 2/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61065 | 0.88 | — | — | |
| SCHEMBL61064 | 0.88 | — | — | |
| SCHEMBL887143 | 0.88 | — | — | |
| SCHEMBL10530673 | 0.84 | ENPEP (0.52) | BLMPMP22KMT2ACYP2D6NFKB1 | |
| SCHEMBL11322855 | 0.84 | CYP2D6 (0.34) | CYP2D6NFKB1LMNAMAPTENPEP | |
| SCHEMBL11453652 | 0.84 | ENPEP (0.52) | BLMPMP22KMT2ACYP2D6NFKB1 | |
| SCHEMBL11054393 | 0.79 | — | — | |
| SCHEMBL10944752 | 0.79 | — | — | |
| SCHEMBL10940176 | 0.79 | — | — | |
| SCHEMBL2593867 | 0.77 | CHRM2 (0.39) | ALOX15BLMPMP22KMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112174849-A | Preparation method and equipment of L-asparagine | 浙江天瑞化学有限公司 | 2021-01-05 | — | — | CN | disclosed |
| EP-2537029-A1 | METHODS OF DIAGNOSING INFLAMMATORY DISEASES BY DETERMINING PYROGLUTAMATE-MODIFIED MCP-1 AND SCREENING METHODS FOR INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-8338120-B2 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor such as 1-(3-(1H-imidazole-1-yl)propyl)-3-(3,4-dimethoxy-phenyl)thiourea hydrochloride; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders; dementia | PROBIODRUG AG (DE) | 2012-12-25 | — | — | US | disclosed |
| EP-2481408-A2 | New use of glutaminyl cyclase inhibitors | Probiodrug AG (DE) | 2012-08-01 | — | — | EP | disclosed |
| US-20120184518-A1 | METHODS OF TREATING OR PREVENTING AN INFLAMMATORY DISEASE OR CONDITION USING GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20110212853-A1 | NOVEL DIAGNOSTIC METHOD | PROBIODRUG AG (DE) | 2011-09-01 | — | — | US | disclosed |
| WO-2011101433-A1 | METHODS OF DIAGNOSING INFLAMMATORY DISEASES BY DETERMINING PYROGLUTAMATE-MODIFIED MCP-1 AND SCREENING METHODS FOR INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2011-08-25 | — | — | WO | disclosed |
| EP-2289498-A1 | Use of inhibitors of glutaminyl clyclase | Probiodrug AG (DE) | 2011-03-02 | — | — | EP | disclosed |
| EP-2117540-A1 | NEW USE OF GLUTAMINYL CYCLASE INHIBITORS | Probiodrug AG (DE) | 2009-11-18 | — | — | EP | disclosed |
| US-20090068699-A1 | USE OF GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2009-03-12 | — | — | US | disclosed |
| WO-2008104580-A1 | NEW USE OF GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-09-04 | — | — | WO | disclosed |
| EP-1622870-A2 | GLUTAMINYL BASED DP IV-INHIBITORS | Prosidion Ltd. (GB) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004099134-A2 | GLUTAMINYL BASED DP IV-INHIBITORS | PROSIDION LTD. (GB) | 2004-11-18 | — | — | WO | disclosed |
| US-20040229848-A1 | Glutaminyl based DP IV-inhibitors | PROSIDION LIMITED (GB) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229848-A1 | Glutaminyl based DP IV-inhibitors | DPP4, DPP3, DNPEP | ALOX15 4131/4885BLM 3796/4885PMP22 2783/4885 |
| US-20090068699-A1 | USE OF GLUTAMINYL CYCLASE INHIBITORS | QPCT, GGCT, GLS | ALOX15 815/4885BLM 3720/4885PMP22 242/4885 |
| US-20120184518-A1 | METHODS OF TREATING OR PREVENTING AN INFLAMMATORY DISEASE OR CONDITION USING GLUTAMINYL CYCLASE INHIBITORS | QPCT, GGCT, GLUL | ALOX15 517/4885BLM 3004/4885PMP22 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.